Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients

Ana Serrano-Combarro¹, Belén Atienza-Mateo², libe Ibarrola-Paino³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Alba Perez Linaza⁶, Santos Castañeda⁷, Rafaela Ortega Castro⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Elena Cañadillas-Sanchez¹², Miriam Retuerto-Guerrero¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Marta López²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Maria Martin-Lopez³¹, Juan Maria Blanco-Madrigal³², Cristina Arciniega³³, Ignacio Brana Abascal³⁴, Jesus Loarce-Martos³⁵, Emilio Giner-Serret³⁶, Virginia Ruiz-Esquide³⁷, Clara ventin-Rodriguez³⁸, Marina Rodriguez-lopez³⁹, Pablo Andujar-Brazal⁴⁰, Julia Fernandez-Melon⁴¹, Lilian Maria Lopez⁴², Antonio Juan Mas⁴³, carlos Fernandez-Diaz⁴⁴, Javier Loricera⁴⁵, Diego Ferrer⁴⁶ and Ricardo Blanco⁴⁷, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶SERV. REUMATOLOGIA, Cadiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Rheumatology, Hospital Universitario de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Arava, Pamplona, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Hospital 12 de Octubre, Madrid, Spain, ³²Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³³Hospital de Mérida, Mérida, Spain, ³⁴Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁵Ramón y Cajal University Hospital, Madrid, Spain, ³⁶Hospital Royo Villanova, Teruel, Spain, ³⁷Hospital Clinic, Rheumatology, Barcelona, Spain, ³⁸Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁹Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴³Son Llazter University Hospital, Palma, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), interstitial lung disease, rheumatoid arthritis

Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD. Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration of ABA for articular manifestations. However, it has not been studied in RA-ILD. Our objective was tocompare the effectiveness of ABA in RA-ILD patients according to the route of administration (IV-ABA vs SC-ABA).

Methods: National multicenter study of RA-ILD patients on treatment with ABA. They were divided into 2 groups according to the route of administration: a) IV, and b) SC. We analyzed from baseline the following outcomes in both groups: a) forced vital capacity (FVC), b) diffusing capacity of the lungs for carbon monoxide (DLCO), c) chest high resolution computed tomography (HRCT), d)dyspnea (assessed with the modified Medical Research Council scale), e) arthritis activity (assessed with DAS28-ESR or described in clinical records), and f) sparing corticosteroids effect.

Results: We studied a total of 509 [SC-ABA/IV-AB; 360/100 (available data)] patients. Baseline demographic and clinical characteristics are shown in Table 1.Patients were followed-up for a median [IQR] of 24 [7-48] months.FVC and DLCO remain stable during the first 24 months in both SC-ABA and IV-ABA [Figure 1]. Dyspnea stabilized or improved in 84% of patients (89% of IV-ABA; 82% of SC-ABA). ABA was withdrawn in 106 patients: 81(34%) in SC-ABA group and 25 (40%) in IV-ABA group. ILD worsening and articular inefficacy were the most common reasons of ABA discontinuation.

Conclusion: In RA-ILD, ABA seems equally effective and safe regardless of the route of administration IV or SC.

Table 1. Main general features at baseline of RA-ILD patients with subcutaneous vs intravenous ABA.

Figure 1. Evolution of pulmonary function tests (mean % of the predicted FVC and DLCO) in RA-ILD patients with SC-ABA vs IV-ABA therapy at baseline and 24 months.

Disclosures: A. Serrano-Combarro: None; B. Atienza-Mateo: None; l. Ibarrola-Paino: None; I. Casafont-Sole: None; R. Melero-Gonzalez: None; A. Perez Linaza: None; S. Castañeda: None; R. Ortega Castro: None; N. Mena Vazquez: None; N. Vegas Revenga: None; L. Dominguez Casas: None; E. Cañadillas-Sanchez: None; M. Retuerto-Guerrero: None; L. Perez-Albadalejo: None; R. Lopez-Sanchez: None; M. MANZANO CANABAL: None; A. Brandy-Garcia: None; P. Lopez-Viejo: None; G. Bonilla: None; O. Maiz-Alonso: None; C. carrasco-Cubero: None; M. Garijo Bufort: None; M. Moreno: None; A. Urruticoechea: None; S. Ordonez-Palau: None; C. Gonzalez-Montagut Gomez: None; a. Garcia-Valle: None; M. López: None; F. Lozano: None; T. Vazquez-Rodriguez: None; M. Martin-Lopez: None; J. Blanco-Madrigal: None; C. Arciniega: None; I. Brana Abascal: None; J. Loarce-Martos: Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 6, Galapagos, 6; E. Giner-Serret: None; V. Ruiz-Esquide: None; C. ventin-Rodriguez: None; M. Rodriguez-lopez: None; P. Andujar-Brazal: None; J. Fernandez-Melon: None; L. Lopez: None; A. Juan Mas: None; c. Fernandez-Diaz: None; J. Loricera: None; D. Ferrer: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Serrano-Combarro A, Atienza-Mateo B, Ibarrola-Paino l, Casafont-Sole I, Melero-Gonzalez R, Perez Linaza A, Castañeda S, Ortega Castro R, Mena Vazquez N, Vegas Revenga N, Dominguez Casas L, Cañadillas-Sanchez E, Retuerto-Guerrero M, Perez-Albadalejo L, Lopez-Sanchez R, MANZANO CANABAL M, Brandy-Garcia A, Lopez-Viejo P, Bonilla G, Maiz-Alonso O, carrasco-Cubero C, Garijo Bufort M, Moreno M, Urruticoechea A, Ordonez-Palau S, Gonzalez-Montagut Gomez C, Garcia-Valle a, López M, Lozano F, Vazquez-Rodriguez T, Martin-Lopez M, Blanco-Madrigal J, Arciniega C, Brana Abascal I, Loarce-Martos J, Giner-Serret E, Ruiz-Esquide V, ventin-Rodriguez C, Rodriguez-lopez M, Andujar-Brazal P, Fernandez-Melon J, Lopez L, Juan Mas A, Fernandez-Diaz c, Loricera J, Ferrer D, Blanco R. Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/subcutaneus-vs-intravenous-abatacept-in-rheumatoid-arthritis-interstitial-lung-disease-national-multicenter-study-of-509-patients/. Accessed .

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneus-vs-intravenous-abatacept-in-rheumatoid-arthritis-interstitial-lung-disease-national-multicenter-study-of-509-patients/